Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis — TEN

Toxic Epidermal Necrolysis Clinical Trial

Official title:
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis: Two-arm, Open, Single-center Study

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06119490
Study type	Interventional
Source	Fujian Provincial Hospital
Contact	Chao Ji
Phone	+86 18651619908
Email	jichaofy@fjmu.edu.cn
Status	Recruiting
Phase	Early Phase 1
Start date	July 5, 2023
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04711200` - LYell SYndrome MEsenchymal Stromal Cells Treatment	Phase 1/Phase 2
Completed	`NCT01696500` - Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.	Phase 3
Terminated	`NCT02037347` - Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis	Phase 1/Phase 2
Withdrawn	`NCT02319616` - Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis	Phase 1/Phase 2
Withdrawn	`NCT02795143` - Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study	N/A
Withdrawn	`NCT00372723` - Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)	Phase 2
Recruiting	`NCT02574988` - Severe Cutaneous Adverse Reactions in Thailand
Not yet recruiting	`NCT03585946` - Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis